To understand Atomwise, it helps to know a little about how drug discovery works.
Researchers first identify the biological cause of a disease — usually a protein — to target with a treatment. A protein may help a tumor grow or cause inflammation, for example. Next they search for a medicine that will hit that target, inhibiting or boosting its function.
The company’s AtomNet deep learning software sifts through millions of possible molecules for effective treatments. It then analyzes stimulations that show how the potential medicine will behave in the human body.
The software predicts whether the treatment works against the target, how it affects other parts of the body, its toxicity and possible side effects. Atomwise uses our Tesla V100 and other NVIDIA GPUs for both training and inference on AtomNet.
Read the full article in NVIDIA's blog.
About Atomwise
Atomwise is revolutionizing how drugs are discovered with AI. We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. We are tackling over 600 unique disease targets across 775 collaborations spanning more than 250 partners around the world. Our portfolio of joint ventures and partnerships with leading pharmaceutical, agrochemical, and emerging biotechnology companies represents a collective deal value approaching $7 billion. Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster.
